Leah H Rubin1,2, Ned Sacktor1, Jason Creighton1, Yong Du3, Christopher J Endres3, Martin G Pomper3, Jennifer M Coughlin4. 1. Department of Neurology, Johns Hopkins University School of Medicine. 2. Department of Epidemiology, Bloomsburg School of Public Health. 3. Russell H. Morgan Department of Radiology and Radiological Science. 4. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: Despite viral suppression, HIV-associated cognitive impairment persists and may be partially due to persistent immune signalling by cells of the myeloid-lineage. Here, we aimed to understand the contribution of activated microglia located in vulnerable brain regions (e.g. frontal, subcortical) of HIV-infected, virally suppressed (HIV+VS) individuals in relation to cognitive and motor function. DESIGN: Twenty-one HIV+VS individuals underwent PET with [11C]DPA-713 to image the translocator protein 18 kDa (TSPO), a marker of microglial activation, and completed a comprehensive neuropsychological test battery. METHODS: Multivariable linear regressions were used to examine the contribution of [11C]DPA-713 binding to cognitive performance. RESULTS: Higher [11C]DPA-713 binding was associated with lower cognition among HIV+VS individuals. [11C]DPA-713 binding in middle frontal gyrus/frontal cortex, hippocampus/temporal cortex and occipital cortex was inversely associated with performance on a number of cognitive domains, including verbal memory, processing speed/attention/concentration, executive function, working memory and motor function. [C]DPA-713 binding in parietal cortex, cerebellum and thalamus was associated with only specific cognitive domains including visual construction and verbal memory. Binding was not associated with global cognitive performance. CONCLUSION: The findings add to the growing body of evidence that immune-mediated brain injury may contribute to domain specific, HIV-associated, cognitive vulnerabilities despite viral suppression.
OBJECTIVE: Despite viral suppression, HIV-associated cognitive impairment persists and may be partially due to persistent immune signalling by cells of the myeloid-lineage. Here, we aimed to understand the contribution of activated microglia located in vulnerable brain regions (e.g. frontal, subcortical) of HIV-infected, virally suppressed (HIV+VS) individuals in relation to cognitive and motor function. DESIGN: Twenty-one HIV+VS individuals underwent PET with [11C]DPA-713 to image the translocator protein 18 kDa (TSPO), a marker of microglial activation, and completed a comprehensive neuropsychological test battery. METHODS: Multivariable linear regressions were used to examine the contribution of [11C]DPA-713 binding to cognitive performance. RESULTS: Higher [11C]DPA-713 binding was associated with lower cognition among HIV+VS individuals. [11C]DPA-713 binding in middle frontal gyrus/frontal cortex, hippocampus/temporal cortex and occipital cortex was inversely associated with performance on a number of cognitive domains, including verbal memory, processing speed/attention/concentration, executive function, working memory and motor function. [C]DPA-713 binding in parietal cortex, cerebellum and thalamus was associated with only specific cognitive domains including visual construction and verbal memory. Binding was not associated with global cognitive performance. CONCLUSION: The findings add to the growing body of evidence that immune-mediated brain injury may contribute to domain specific, HIV-associated, cognitive vulnerabilities despite viral suppression.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: T Notter; J M Coughlin; T Gschwind; U Weber-Stadlbauer; Y Wang; M Kassiou; A C Vernon; D Benke; M G Pomper; A Sawa; U Meyer Journal: Mol Psychiatry Date: 2017-01-17 Impact factor: 15.992
Authors: Brandon M Imp; Leah H Rubin; Phyllis C Tien; Michael W Plankey; Elizabeth T Golub; Audrey L French; Victor G Valcour Journal: J Infect Dis Date: 2016-10-26 Impact factor: 5.226
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Lucy J Garvey; Nicola Pavese; Marios Politis; Anil Ramlackhansingh; David J Brooks; Simon D Taylor-Robinson; Alan Winston Journal: AIDS Date: 2014-01-02 Impact factor: 4.177
Authors: Ryan P Bell; Sheri L Towe; Zahra Lalee; Scott A Huettel; Christina S Meade Journal: Cogn Affect Behav Neurosci Date: 2020-08 Impact factor: 3.282
Authors: Tamas Fulop; Jacek M Witkowski; Anis Larbi; Abdelouahed Khalil; Georges Herbein; Eric H Frost Journal: J Neurovirol Date: 2019-03-13 Impact factor: 2.643
Authors: Eva M Müller-Oehring; Rosemary Fama; Taylor F Levine; Cheshire Hardcastle; Ryan Goodcase; Talora Martin; Varsha Prabhakar; Helen M Brontë-Stewart; Kathleen L Poston; Edith V Sullivan; Tilman Schulte Journal: J Neuropsychol Date: 2020-10-08 Impact factor: 2.864
Authors: William C Kreisl; Min-Jeong Kim; Jennifer M Coughlin; Ioline D Henter; David R Owen; Robert B Innis Journal: Lancet Neurol Date: 2020-11 Impact factor: 44.182